妊娠期甲状腺功能试验:验证与建立妊娠期特异性参考区间的实用方法
本研究旨在验证厂商推荐的妊娠期甲状腺功能试验参考区间及美国甲状腺协会推荐的妊娠期总甲状腺素(TT4)参考区间是否适用于作者所在的多文化人群。研究采集了妊娠早、中、晚期的血样,排除使用甲状腺药物、有甲状腺疾病及甲状腺过氧化物酶抗体(anti-TPO)阳性的样本,使用Roche Cobas 8000 e602电化学发光免疫分析法检测。结果显示厂商推荐的促甲状腺激素(TSH)妊娠期参考区间未通过标准化方法验证,因此研究确定了TSH、游离甲状腺素(fT4)和TT4的妊娠期参考区间,其中TT4参考区间低于美国甲状腺协会推荐的区间。
要点
- 厂商推荐的TSH妊娠期参考区间未通过标准化方法验证,需本地建立。
- 研究确定了妊娠早、中、晚期TSH和fT4的参考区间。
- 妊娠19周后TT4参考区间为77-186 nmol/L,低于美国甲状腺协会推荐。
核心结论
- 本研究提供了一种验证或建立本地人群妊娠期甲状腺功能参考区间的简单方法。
- 厂商推荐的TSH妊娠期参考区间未通过标准化方法验证,因此研究确定了基于95百分位的参考区间。
- TT4参考区间低于美国甲状腺协会推荐的区间,提示需要进一步研究妊娠期TT4,并在19周后依赖本地建立的fT4参考区间。
研究设计与样本
- 研究采集了妊娠早、中、晚期的血样,样本来源包括:常规非整倍体筛查的剩余冻存血(妊娠早、中期,n=274)、观察性队列研究参与者(妊娠中、晚期,n=135)以及待产病房就诊孕妇(妊娠晚期,n=35)。
- 排除标准包括使用甲状腺药物、有甲状腺疾病及anti-TPO阳性。
- 使用Roche Cobas 8000 Modular e602电化学发光免疫分析法检测TSH、fT4、游离三碘甲状腺原氨酸(fT3)、TT4和anti-TPO。
主要发现
- 9%的非整倍体筛查样本因母亲使用甲状腺药物而在甲状腺检测前被排除。
- 6%的分析样本被排除:5.9% anti-TPO阳性,1例TSH>10 mIU/L。
- TSH和fT4参考区间:妊娠9-12周分别为0.18-2.99 mIU/L和11-19.2 pmol/L;妊娠中期分别为0.11-3.98 mIU/L和10.5-18.2 pmol/L;妊娠晚期分别为0.48-4.71 mIU/L和9.0-16.1 pmol/L。
- 妊娠19周后TT4参考区间为77-186 nmol/L。
关键数值与推荐
- TSH参考区间:妊娠9-12周0.18-2.99 mIU/L;妊娠中期0.11-3.98 mIU/L;妊娠晚期0.48-4.71 mIU/L。
- fT4参考区间:妊娠9-12周11-19.2 pmol/L;妊娠中期10.5-18.2 pmol/L;妊娠晚期9.0-16.1 pmol/L。
- TT4参考区间:妊娠19周后77-186 nmol/L。
临床怎么用
- 在临床实践中,应验证或建立本地人群的妊娠期特异性甲状腺功能参考区间,而非直接使用厂商推荐值。
- 妊娠19周后,尤其在没有等效TT4参考区间时,应依赖本地建立的fT4参考区间评估甲状腺功能。
- 本研究提供的简单方法可用于其他人群验证或建立妊娠期甲状腺功能参考区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Population-, assay-, and trimester-specific reference intervals for thyroid function tests are necessary to assess thyroid status accurately and manage thyroid disease throughout pregnancy. This study's objective was to verify if the manufacturer's recommended trimester-specific reference intervals for thyroid tests and the American Thyroid Association's recommended total thyroxine (TT4) pregnancy reference intervals were verifiable and appropriate for use in the authors' multicultural population. METHODS: Blood samples were obtained from the following sources: stored frozen surplus blood from women undergoing routine aneuploidy screening (first- and second-trimester samples, n = 274), women participating in an observational cohort study (second- and third-trimester samples, n = 135), and blood collected from women presenting for assessment to the labor and delivery ward (third-trimester samples, n = 35). Exclusions included thyroid medication or disease and positive thyroid peroxidase antibodies (anti-TPO). Samples were analyzed for thyrotropin (TSH), free T4 (fT4), free triiodothyronine (fT3), TT4, and anti-TPO using the Roche Cobas 8000 Modular e602 electrochemiluminescence immunoassay. RESULTS: Nine percent of the aneuploidy screening samples were excluded prior to thyroid testing due to maternal use of thyroid medication. Six percent of analyzed samples were excluded: 5.9% with positive anti-TPO and one with a TSH >10 mIU/L. The manufacturer's recommended trimester-specific reference intervals for TSH were not verified by described standardized methods. Therefore, 95th percentile reference intervals were determined using a minimum number of samples. Reference intervals for TSH and fT4 were as follows: 9-12 weeks, 0.18-2.99 mIU/L and 11-19.2 pmol/L; second trimester, 0.11-3.98 mIU/L and 10.5-18.2 pmol/L; and third trimester, 0.48-4.71 mIU/L and 9.0-16.1 pmol/L, respectively. The TT4 reference interval after 19 weeks' gestation was 77-186 nmol/L. CONCLUSIONS: This study provides a simple approach to verify or establish trimester-specific thyroid function reference intervals in local populations. The TT4 reference interval was lower than the interval proposed by the American Thyroid Association, suggesting the need for further study of TT4 in pregnancy and reliance on locally established fT4 reference intervals after 19 weeks, especially when there are no equivalent reference intervals for TT4.
引用
- Donovan LE, Metcalfe A, Chin A, et al. A Practical Approach for the Verification and Determination of Site- and Trimester-Specific Reference Intervals for Thyroid Function Tests in Pregnancy. Thyroid. 2019. PMID: 30595114. doi:10.1089/thy.2018.0439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。